| Drug Name |
Letrozole |
| Drug ID |
BADD_D01257 |
| Description |
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine.[A190546]
Letrozole was granted FDA approval on 25 July 1997.[L11623] |
| Indications and Usage |
For the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. Also for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L02BG04 |
| DrugBank ID |
DB01006
|
| KEGG ID |
D00964
|
| MeSH ID |
D000077289
|
| PubChem ID |
3902
|
| TTD Drug ID |
D0C1WH
|
| NDC Product Code |
55111-646; 55111-809; 42291-374; 57884-0011; 68554-0039; 71205-587; 0093-7620; 50090-3474; 63592-3376; 16729-034; 51991-759; 63850-7723; 63850-0025; 13808-514; 65096-0116; 0078-0249; 62135-491; 71335-1526; 62756-235; 57884-2021; 59651-180; 69988-0014; 65129-1130; 50268-476; 63850-7701; 63629-7819; 58623-0099 |
| Synonyms |
Letrozole | 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile) | CGS 20267 | CGS-20267 | CGS20267 | Femara | Fémara |
